Market closedADR
Teva Pharmaceutical/$TEVA
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Teva Pharmaceutical
Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
Ticker
$TEVA
Sector
Trading on
NYSE
Industry
Pharmaceuticals
Headquarters
Tel Aviv, Israel
Employees
34,789
Website
TEVA Metrics
BasicAdvanced
$19B
-
-$1.45
0.71
-
Price and volume
Market cap
$19B
Beta
0.71
52-week high
$22.80
52-week low
$11.83
Average daily volume
12M
Financial strength
Current ratio
0.981
Quick ratio
0.497
Long term debt to equity
285.245
Total debt to equity
317.902
Interest coverage (TTM)
3.37%
Management effectiveness
Return on assets (TTM)
5.09%
Return on equity (TTM)
-28.30%
Valuation
Price to revenue (TTM)
1.151
Price to book
3.55
Price to tangible book (TTM)
-1.34
Price to free cash flow (TTM)
25.414
Growth
Revenue change (TTM)
4.40%
Earnings per share change (TTM)
190.00%
3-year revenue growth (CAGR)
1.38%
3-year earnings per share growth (CAGR)
56.48%
What the Analysts think about TEVA
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Teva Pharmaceutical stock.
TEVA Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
TEVA Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
TEVA News
AllArticlesVideos
Axsome Therapeutics Resolves Generic Patent Litigation With Teva Over Depression Drug, Analyst Maintains Axsome As 'Top Pick For 2025'
Benzinga·19 hours ago
Completion of the Pivotal Phase 3 Trial for Olanzapine LAI in Schizophrenia Conducted by Teva Pharmaceuticals
Business Wire·1 day ago
Teva Pharma: Why This Generic Drug Giant Is a Smart Buy Now
MarketBeat·1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Teva Pharmaceutical stock?
Teva Pharmaceutical (TEVA) has a market cap of $19B as of February 11, 2025.
What is the P/E ratio for Teva Pharmaceutical stock?
The price to earnings (P/E) ratio for Teva Pharmaceutical (TEVA) stock is 0 as of February 11, 2025.
Does Teva Pharmaceutical stock pay dividends?
No, Teva Pharmaceutical (TEVA) stock does not pay dividends to its shareholders as of February 11, 2025.
When is the next Teva Pharmaceutical dividend payment date?
Teva Pharmaceutical (TEVA) stock does not pay dividends to its shareholders.
What is the beta indicator for Teva Pharmaceutical?
Teva Pharmaceutical (TEVA) has a beta rating of 0.71. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.